INTRODUCTION {#s1}
============

Aortic aneurysms(AAs) are a common cause of sudden death. Most AAs are discovered accidentally, but progressive aneurysmal enlargement can lead to rupture. As a result of increased surveillance and surgical innovations, the rate of AA-related mortality has decreased drastically \[[@R1]\]. Previous small-scale clinical observational studies have shown that cardiovascular disease (CVD) events were the most frequent cause of death after endovascular surgery, whereas malignancy-related death accounted for 14.5--29% of deaths after endovascular surgery, following CVD- and AA-related deaths (35%) \[[@R2]\]. Although commonly considered two separate disease entities, CVD and malignancy have numerous similarities and possible interactions, as they share several risk factors, epidemiological features and biological signaling pathways \[[@R3]\].

Advances in molecular biological techniques have led to the discovery of increasing evidence suggesting that several related biological signaling pathways are associated with the development of malignancies and AAs. Recent studies have shown that the transforming growth factor-β (TGF-β), mitogen-activated protein kinase (MAPK),and hypoxia inducible factor-1α (HIF-1α) pathways in addition to inflammatory pathways regulate malignant cell initiation, proliferation, migration and invasion \[[@R4]--[@R6]\] and that these pathways are also active participants in the pathogenesis of AAs.

Specifically, TGF-β signaling overactivation is associated with Marfan syndrome (MFS) and several MFS-like conditions. Those diseases are also clearly associated with non-inflammatory structural degenerative CVDs, including aortic root dilatation, thoracic aneurysms and aortic dissection \[[@R7], [@R8]\]. In tumor cells, TGF-β loses its anti-proliferative characteristics and becomes an oncogenic factor, which leads to impairments in its signaling pathway in various solid tumors and hematological malignancies \[[@R9]\].

Studies regarding the associations between AAs and subsequent or concurrent malignancies are scarce. Thus, we aimed to determine whether patients with aortic diseases have an increased risk of malignancy using a nationwide health care insurance claim database.

RESULTS {#s2}
=======

A flow diagram of our patient enrollment scheme is presented in Figure [1](#F1){ref-type="fig"}. A total of 10,933 patients diagnosed with AA were identified in the National Health Insurance Research Database (NHIRD), which contains a total of 986,713 patients. Another 43,732 age-, gender-, and comorbidity-matched patients were designated controls. As shown in Table [1](#T1){ref-type="table"}, as expected, there were no significant differences in gender, age and co-morbidities, including hypertension, hyperlipidemia, diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD), between the two groups after matching. There were also no significance differences between the two groups with regard to medication use. Table [2](#T2){ref-type="table"} shows the incidences of malignancies during the ten-year follow-up period. At the end of the follow-up period, patients with an AA had significantly higher incidences of hypertension (54.60% vs. 31.17%, *p* = 0.001) and hyperlipidemia (3.54% vs. 2/65%, *p* \< 0.001) but lower incidences of DM (10.68% vs. 15.93%, *p* \< 0.001) and COPD (7.28% vs. 13.21%, *p* \< 0.001) than patients without an AA.

![Patient selection flowchart AA = aortic aneurysm](oncotarget-09-2829-g001){#F1}

###### Baseline characteristics of patients included in the study

                       Patients with AA N = 10,933   Patients without AA N = 43,732   *p* value
  -------------------- ----------------------------- -------------------------------- -----------
  Gender                                                                              0.999
   Male                7,783 (71.19%)                31,132 (71.19%)                  
   Female              3,150 (28.81%)                12,600 (28.81%)                  
  Age (years)          63.25±14.30                   65.50±15.78                      0.121
  Age groups (years)                                                                  0.386
   20--49              2.745 (25.11%)                9,127 (20.87%)                   
   50--65              1,660 (15.18%)                8,560 (19.57%)                   
   \> 65               6,528 (59.71%)                26,045 (59.56%)                  
  Comorbidities                                                                       
   Hypertension        6,522 (59.65%)                26,088 (59.65%)                  0.999
   Diabetes            992 (9.07%)                   3,968 (9.07%)                    0.999
   Hyperlipidemia      400 (3.66%)                   1,600 (3.66%)                    0.999
   COPD                663 (6.06%)                   2,652 (6.06%)                    0.999
  Medicine                                                                            
   β-blockers          2,721 (24.89%)                11,167 (25.54%)                  0.462
   CCBs                2,820 (25.79%)                11,611 (26.55%)                  0.338
   ACEIs               2,632 (24.07%)                10,637 (24.32%)                  0.296
   ARBs                2,391 (21.87%)                9,580 (21.91%)                   0.475
   Diuretics           2,290 (20.95%)                8,967 (20.50%)                   0.556
   Statins             2,484 (22.72%)                9,725 (22.24%)                   0.279

COPD = chronic obstructive pulmonary disease; CCBs = calcium channel blockers; ACEIs = angiotensin-converting-enzyme inhibitors; ARBs = angiotensin receptor blockers.

###### Factors of malignancy with catastrophic illness at the end of follow-up stratified according to the variables listed in the table based on Cox regression

                   Patients with AA   Patients without AA   Ratio      Adjusted HR^\*^   95% CI      p value                                   
  ---------------- ------------------ --------------------- ---------- ----------------- ----------- ---------- ------- ------- -------------- ----------
  Total            396                15,140.57             2,615.49   1,726             85,732.47   2,013.24   1.299   2.753   2.452--3.090   \< 0.001
  Age                                                                                                                                          
   20--49          19                 1,533.39              1,239.08   90                8,086.30    1,112.99   1.113   2.256   1.975--2.552   \< 0.001
   50--65          87                 4,231.04              2,056.23   221               12,280.43   1,799.61   1.143   2.458   2.110--2.715   \< 0.001
   \> 65           290                9,374.14              3,093.62   1,415             64,645.74   2,188.85   1.413   2.976   2.445--3.469   \< 0.001
  Gender                                                                                                                                       
   Male            293                10892.31              2,689.97   1,311             62,108.09   2,110.84   1.274   2.697   2.358--3.085   \< 0.001
   Female          103                4,248.46              2,424.41   415               23624.38    1,756.66   1.380   2.926   2.329--3.675   \< 0.001
  Comorbidities†                                                                                                                               
   With            206                5,855.79              3,517.89   1,017             39,465.57   2,576.93   1.365   2.769   2.373--3.232   \< 0.001
   Without         190                9,284.78              2,046.36   709               46,266.90   1,532.41   1.335   2.975   2.507--3.530   \< 0.001

*p* values are for the adjusted HRs. PY = person-years. HR = hazard ratio. Events = number of cancer diagnoses. ^\*^Adjusted HR was adjusted for age, sex, and comorbidities. †Comorbidities included hypertension, diabetes, hyperlipidemia and chronic obstructive pulmonary disease.

Patients with an AA had a significantly higher cumulative risk of developing malignancies in subsequent years than patients without an AA (log rank test \< 0.001, Figure [2A](#F2){ref-type="fig"}). Similarly, patients with malignancies had a significantly higher cumulative risk of developing an AA in subsequent years than patients without malignancies(log rank test \< 0.001, Figure [2B](#F2){ref-type="fig"}). Patients with an AA had a significantly higher risk of developing malignancies than patients without an AA, independent of the effects of gender, age and co-morbidities (Table [2](#T2){ref-type="table"}).

![(**A**) The Kaplan-Meier curve for the cumulative risk of malignancy events by AA (log rank *p* \< 0.001) (**B**). The Kaplan-Meier curve for the cumulative risk of AA events by malignancy (log rank *p* \< 0.001) AA = aortic aneurysm.](oncotarget-09-2829-g002){#F2}

As shown in Table [3](#T3){ref-type="table"}, AAs were associated with both hematological malignancies and solid malignancies. Among solid malignancies, head and neck, liver, pancreas, lung, skin, breast, cervix, prostate, bladder, and kidney malignancies were significantly associated with AAs. The remaining malignancies, which were not significantly associated with AAs, are shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

###### Comparison of individual malignancy risk in the AA cohort and the control cohort

                                      Patients with AA   Patients without AA   Ratio   Adjusted HR^\*^   95% CI   p value                    
  ----------------------------------- ------------------ --------------------- ------- ----------------- -------- --------- ---------------- ----------
  Head and neck                       29                 191.54                116     135.30            1.416    1.514     1.016--2.300     0.025
  Colon                               38                 250.98                161     187.79            1.336    3.394     2.326--4.952     \< 0.001
  Rectum                              26                 171.72                97      113.14            1.518    2.805     1.454--1.767     \< 0.001
  Liver and intrahepatic bile ducts   64                 422.71                312     363.92            1.162    2.588     1.953--3.431     \< 0.001
  Pancreas                            10                 66.05                 47      54.82             1.205    2.696     1.313--5.536     0.007
  Retroperitoneum and peritoneum      4                  26.42                 3       3.50              7.550    16.124    3.411--76.223    \< 0.001
  Trachea, bronchus and lung          62                 409.50                257     299.77            1.366    3.278     2.444--4.396     \< 0.001
  Skin                                7                  46.23                 30      34.99             1.321    2.067     1.079--4.862     0.026
  Female breast                       8                  52.84                 38      44.32             1.192    2.812     1.272--6.220     0.011
  Uterus                              2                  13.21                 1       1.17              11.325   21.507    1.725--268.192   0.017
  Cervix                              7                  46.23                 27      31.49             1.468    2.487     1.035--5.971     0.042
  Prostate                            28                 184.93                100     116.64            1.585    4.897     3.135--7.650     \< 0.001
  Bladder                             33                 217.96                81      94.48             2.307    5.206     3.386--8.005     \< 0.001
  Kidney and other urinary organs     21                 138.70                68      79.32             1.749    3.173     1.889--5.329     \< 0.001
  Hematopoietic malignancy†           27                 178.33                139     162.13            1.100    2.464     1.593--3.810     \< 0.001

^\*^Adjusted hazard ratio was adjusted for age, sex and comorbidities. †Hematopoietic malignancy including leukemia and lymphoma.

DISCUSSION {#s3}
==========

The major finding of the study was that patients with an AA have an increased risk of developing both solid and hematological malignancies in subsequent years, even after adjustment for certain co-morbidities, including hypertension, DM, hyperlipidemia and COPD. Patients with malignancies were also prone to developing AAs.

Previous clinical observational studies have shown that an association exists between AAs and increased incidence of malignancy. Serial CT surveillance revealed that the rate of pulmonary malignancies was high in a population with AAs compared with a population without AAs \[[@R10]\]. This finding raised the question of whether increased medical surveillance for AAs may provide clinicians with opportunities diagnose malignancies earlier. Age, male gender, hyperlipidemia, hypertension, obesity and tobacco use are well known risk factors for AA \[[@R11]\]. Several modifiable CVD risk factors are shared between AA and malignancies, including tobacco use, hypertension, obesity and hyperlipidemia \[[@R3]\]. In this study, we found that the patients with an AA had an increased risk of developing both solid and hematological malignancies in subsequent years and vice versa. We hypothesized that these shared risk factors could also contribute to the concurrency of AA and malignancies. Patients with AAs were found to be significantly more likely to develop malignancies than patients without AAs 2 years after their diagnoses of AA, and patients with malignancies were found to be significantly more likely to develop AAs than patients without malignancies 5 years after their diagnoses of malignancy. Based on these findings, we hypothesized that the concurrence of AAs and malignancies may be attributed to risk factors shared by the two diseases, as well as to changes in the activity of biological signaling pathways common to both disease processes. The results of regression analyses performed in previous studies have suggested that age and tobacco use rather than AAs are independent risk factors for the development of cancer \[[@R12]\]. We found that patients with AAs still had a higher risk of developing malignancies than patients without AAs, even after adjustment for age, gender and several co-morbidities. We are aware that certain medications, such as statins and renin--angiotensin system inhibitors, have been shown to have protective effects in the development of experimental AA. Nonetheless, there is no evidence that commonly used cardiovascular drugs have beneficial clinical effects on AA progression \[[@R13]\]. The current evidence is not sufficient to support using aspirin as an adjuvant therapy for colorectal cancer \[[@R14]--[@R16]\]. After matching for co-morbidities, we found that there were no differences regarding those medications. Therefore, the biological signaling pathways that are involved in both AAs and malignancies should be explored to elucidate this relationship further.

Matrix metalloproteinases (MMPs) are proteolytic enzymes, and MMPs expression and activation are regulated in physiological conditions to prevent uncontrolled body tissue destruction. Degradation of the collagen and elastin of the aortic wall is induced by altering of the expression of several catabolic MMPs \[[@R17]\]. Patients with AAs showed significantly higher MMPs expression levels in their aortic tissue than patients without AAs \[[@R18], [@R19]\]. MMPs are known as regulators of the tumor microenvironment, and numerous studies have confirmed the existence of associations between MMPs and tumor growth, tumor apoptosis, tumor vasculature, and neoplastic progression, invasion and metastasis initiation in malignancies \[[@R20], [@R21]\].

Recent studies have provided convincing evidence indicating that several signaling pathways are involved in both AAs and malignancies, including the TGF-β, MAPK JNK, ERK, Rho/ROCK, NF-kb, HIF-1α, and MMPs signaling pathways. The MAPK JNK and ERK pathways are cancer cell proliferation, differentiation, survival, inflammation and drug resistance pathways \[[@R22], [@R23]\], the suppression of which has been shown to reduce the growth of AAs in experimental AA models \[[@R24], [@R25]\]. HIF-1α signaling is associated with tumor metastasis, tumor angiogenesis, and a poor patient prognosis, as well as resistance to tumor therapy \[[@R26]\]. HIF-1α overexpression has been found at the edges of ruptured human AA tissue \[[@R27]\]. In vascular cells, HIF-1α promotes vascular inflammation, MMPs release and vascular remodeling \[[@R28], [@R29]\]. HIF-1α inhibition has been shown to attenuate AA progression through MMP down-regulation \[[@R30]\]. Small molecules developed for anti-cancer purposes have also been shown to be effective in the treatment of experimental AA \[[@R30]--[@R32]\].

TGF-β signaling plays critical roles in the pathogenesis of AAs \[[@R33]\]. Cardiovascular abnormalities are the major cause of morbidity and mortality in MFS and several clinically related diseases, including Loeys-Dietz syndrome, Shprintzen-Goldberg syndrome, aneurysm-osteoarthritis syndrome and thoracic aortic aneurysm syndrome, in which the pathogeneses are driven by dysregulated TGF-β signaling \[[@R8]\]. MFS is characterized by a deficiency of fibrillin-1 (FBN1) in the extracellular matrix. Studies of Marfan murine models have revealed that the TGF-β signaling pathway is heavily involved in the pathogenesis of MFS. In a Korean MFS cohort, up to 89.8% of patients who had FBN1 mutationsin genetic analysis developed aortic root aneurysm/dissection, and 62% of patients underwent some type of cardiovascular surgery. CVD manifestations were commonly detected, and FBN1 mutations were present in approximately 90% of patients \[[@R34]\]. AAs in MFS tended to occur in relatively young patients and are susceptible to dissection and rupture \[[@R35], [@R36]\]. Targeting the over activity of the TGF-β pathway has been proposed as a strategy for treating AAs \[[@R37]\]. TGF-β-induced epithelial-mesenchymal transition and reversion from the mesenchymal to the epithelial phenotype have been increasingly recognized as integral aspects of cancer progression that contribute to malignant cell survival and dissemination \[[@R38]\]. TGF-β actively participates in the pathogenesis of several malignancies \[[@R39]--[@R41]\]. Notably, accumulated case reports have indicated that an association exists between MFS/MFS-like conditions and several hematological and solid malignancies \[[@R42]\]. However, the associations between MFS/MFS-like conditions and malignancies have not been evaluated in large-scale studies.

Limitations {#s3_1}
-----------

The strength of our study was its population-based cohort design. We determined the incidence of cancer by recording both ICD-9 codes and data from the Registry of Catastrophic Illness Patient Database to increase the accuracy of our results. We excluded cofounding factors, including co-morbidities and medication effects, from our analysis. However, there were some limitations to this study. Although we aimed to control for potential disease-associated confounders to the greatest extent possible, unknown or unmeasured confounders may have biased our findings. The NHIRD registry is not able to provide detailed information regarding the laboratory results or health-related lifestyle factors of patients, such as alcohol consumption, tobacco use, body mass indices and family histories, all of which can increase the risk of cancer and were potential confounding factors in this study; however, we considered the incidence of COPD a proxy variable for tobacco use to attenuate its potential confounding effect \[[@R43]\]. Both mechanistic studies and animal experiments are required to further clarify this important issue.

MATERIALS AND METHODS {#s4}
=====================

Data source {#s4_1}
-----------

The data for the nationwide population-based retrospective cohort study described here in were obtained from the Longitudinal Health Insurance Database 2005 (LHID 2005), a subset database of the Taiwan NHIRD. This National Health Insurance program was implemented in 1995 and provides health care coverage for 99% of the population in Taiwan (more than 23 million people). The LHID 2005 contains information on medical service utilization by a randomly selected sample of approximately one million beneficiaries, who represent approximately 5% of Taiwan\'s population, in 2005. The information was extracted from the NHIRD between 2000 and 2010. The accuracy of the diagnoses in the NHIRD, namely, the diagnoses of major diseases such as stroke and acute coronary syndrome, has been validated \[[@R44], [@R45]\]. The LHID 2005 consists of "de-identified" secondary data released to the public for research purposes. Patient identification numbers, genders, birthdays, dates of admission and discharge, ICD-9-CM (International Classification of Diseases, 9th Revision, Clinical Modification) diagnostic and procedure codes (up to five each), and outcomes are encrypted, as is information regarding the medical institutions at which patients received their services. This study was conducted in accordance with the Declaration of Helsinki and relevant guidelines and was approved by the Institutional Review Board of Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGH IRB No.B-104-21).

Sampled patients {#s4_2}
----------------

This study featured study and comparison cohorts. Using the LHID 2005, we selected adult patients aged \>18 years who had been newly diagnosed with AAs (ICD-9-CM 441.1--441.9) and were followed up between 2000 and 2010. We excluded patients who had been diagnosed with AAs (ICD-9-CM 441.1--441.9) and cancer (recorded from the Registry of Catastrophic Illness Patient Database) prior to the index date. Patients who suffered mortality within one month after tracking initiation were also excluded from the study. The date of AA diagnosis was used as the index date. The control candidate sampling comparisons were selected from individuals in the LHID 2005 who had no history of AA. The patients and control cohorts were selected by 1:4 matching, according to the following baseline variables: age; sex; co-morbidities, including hypertension (ICD-9-CM 401--405), DM(ICD-9-CM 250), hyperlipidemia (ICD-9-CM 272.0--272.4), and COPD(ICD-9-CM 490--496); and medication history, including β-blocker, calcium channel blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and diuretic history. The index dates for control patients were the same as the corresponding dates for patients with AAs. A similar approach was used for malignancy, as patients with malignancy were identified as the study group, and patients without malignancy were identified as the control group by1:4 matching, according to baseline variables, including age, sex, co-morbidities and medication history.

Outcome measurements {#s4_3}
--------------------

The study outcome was a diagnosis of malignancy during the 10-year follow-up period. Malignancy events were identified from the Registry of Catastrophic Illness Patient Database, a subset of the NHIRD. Patients newly diagnosed with cancer can apply for a catastrophic illness certificate issued by the government. Before issuing a catastrophic illness certificate, a review of medical records, imaging results, and pathology reports is performed by a panel of specialists and experts on the specific disease. The use of both the NHIRD and catastrophic illness certificate to identify the development of malignancies has been well-validated internally and externally in several studies \[[@R44], [@R46], [@R47]\]. ICD-9 codes pertaining to malignancies involving different areas of the body, including malignancies of the head and neck (ICD-9-CM codes 140--149); esophagus (ICD-9-CM 150); stomach (ICD-9-CM 151); small intestine (ICD-9-CM 152); colon and rectum (ICD-9-CM 153--154); liver (ICD-9-CM 155); gallbladder and extrahepatic bile ducts (ICD-9-CM 156); pancreas (ICD-9-CM 157); retroperitoneum and peritoneum (ICD-9-CM 158); nasal cavities, middle ear and accessory sinuses (ICD-9-CM 160); larynx (ICD-9-CM 161); lung (ICD-9-CM 162); pleura (ICD-9-CM 163); thymus, heart and mediastinum (ICD-9-CM 164); bone and articular cartilage (ICD-9-CM 170); connective and other soft tissues (ICD-9-CM 171); skin (ICD-9-CM 172--173); female breast (ICD-9-CM 174); uterus (ICD-9-CM 179); cervix (ICD-9-CM 180); body of the uterus (ICD-9-CM 182); ovary and other uterine adnexa (ICD-9-CM 183); prostate (ICD-9-CM 185); penis and other male genital organs (ICD-9-CM 187); bladder (ICD-9-CM 188); kidney (ICD-9-CM 189); brain (ICD-9-CM 191); thyroid (ICD-9-CM 193); other endocrine glands and related structures (ICD-9-CM 194); and blood (ICD-9-CM 200--208). Another outcome assessed in this study was the cumulative incidence of AA, which was compared between malignancy and non-malignancy patients, during the 10-year follow-up period.

Statistical analysis {#s4_4}
--------------------

The clinical characteristics of the patients enrolled in the study are expressed in numerical form. Categorical variables, which a presented as percentages, were compared using chi-squared tests and Fisher\'s exact test. Continuous variables, which are presented as the mean and standard deviation, were compared using *t-tests*. The primary goal of the study was to determine whether patient clinical characteristics were associated with malignancies. The associations between time-to-event outcomes (prognoses) and clinical characteristics were investigated using Kaplan-Meier survival analysis and multivariate Cox regression analysis with forward stepwise selection. The results are presented as adjusted hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The threshold for statistical significance was *p* \< 0.05. All data analyses were conducted using SPSS software, version 18 (SPSS Inc., Chicago, IL, USA).

CONCLUSIONS {#s5}
===========

Patients with AAs were shown to have a substantially increased risk of developing a variety of malignancies compared with patients without AAs. Thus, increased cancer surveillance may be needed in these patients. Health care professionals should be aware of this increased risk when treating patients with AAs.

SUPPLEMENTARY MATERIALS TABLE {#s6}
=============================
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